Table.

Characteristics of Included Trials

Study	Year	Country	Patients	Comparison Groups	Investigated Variables
Bouras et al43	1999	USA	50	0.5 mg vs placebo 1 mg vs placebo 2 mg vs placebo	Colonic transit time
Bouras et al44	2001	USA	40	2 mg vs placebo 4 mg vs placebo	Colonic transit time, gastric emptying, small bowel transit time
Camilleri et al45	2008	USA, Belgium	620	2 mg vs placebo 4 mg vs placebo	Spontaneous bowel movement per week and HR-QOL measurement and safety
Camilleri et al46	2009	USA	89	0.5 mg vs placebo 1 mg vs placebo 2 mg vs placebo	Adverse events, ECG changes, Holter monitor, pharmacokinetics.
Coremans et al47	2003	Belgium	55	4 mg vs placebo	Efficacy using VAS, complications, bowel function, transit time
Emmanuel et al48	2002	UK	74	1 mg vs placebo	Oro-caecal transit time, visceral sensitivity, HR-QOL and psychological state
Ke et al49	2012	Asia-Pacific region	501	2 mg vs placebo	Spontaneous bowel movement per week, safety and adverse events
Krogh et al50	2002	Denmark	16	1 mg vs placebo 2 mg vs placebo	Transit time, efficacy, bowel function
Mugie et al51	2014	Multicenter	213	2 mg vs placebo	Spontaneous bowel movement per week and HR-QOL measurement
Muller-Nissler et al52	2010	Germany	300	1 mg vs placebo 2 mg vs placebo 4 mg vs placebo	Spontaneous bowel movement per week, frequency of bowel movement, safety, tolerability, HR-QOL for constipation
Poen et al53	1999	Netherlands	24	1 mg vs placebo 2 mg vs placebo	Total transit time, mean transit time and anorectal physiology studies
Quigley et al54	2009	Ireland	641	2 mg vs placebo 4 mg vs placebo	Spontaneous bowel movement per week and HR-QOL measurement and tolerability
Sloots et al55	2002	Netherlands	37	1 mg vs placebo 2 mg vs placebo	Anorectal physiological study, bowel diary, transit time and rectal compliance/sensitivity
Sloots et al56	2010	Netherlands	196	2 mg vs placebo 4 mg vs placebo	Spontaneous bowel movement per week, safety and adverse events
Tack et al57	2009	Belgium	713	2 mg vs placebo 4 mg vs placebo	Spontaneous bowel movement per week and HR-QOL measurement
Yiannakou et al58	2015	Multicenter	374	2 mg vs placebo	HR-QOL, constipation severity, spontaneous bowel movements per week

HR-QOL, Health related quality of life; ECG, electrocardiogram; VAS, visual analogue scale.